Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nicole Lapuyade"'
Autor:
Alexey Berezhnoy, Michael Winter, Hsin Wang, Nicole Lapuyade, Madan Paidhungat, Dylan Daniel, Marcia Belvin, Erwan Le Scolan, Carol LePage, Leila Boustany, Benjamin Povinelli, Kamaljeet Kaur, Olga Vasiljeva, Vangipuram Rangan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fbf2d1ea625e41a9a4c5a994324f8ff9
Autor:
Kenneth Wong, Alexey Berezhnoy, Robert Dunn, Hsin Wang, Na Cai, Hikmat Assi, Nicole Lapuyade, Madan Paidhungat, Michael Krimm, Dylan Daniel, Marcia Belvin, Erwan Le Scolan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/f195c863a8c74e5db26e8c06c755826f
Autor:
Andrew Jang, Kimberly Ann Tipton, Chihunt Wong, Bryan Irving, Olga Vasiljeva, Margaret Nguyen, Victoria Singson, Vangipuram Rangan, W. Michael Kavanaugh, James William West, Jason Gary Sagert, Michael Krimm, Chanty Chan, Jennifer Richardson, Li Mei, Madan M. Paidhungat, Ruth Villanueva, Jennifer Razo, Hikmat Assi, Linnea Diep, Marcia Belvin, Shouchun Liu, Bruce Howng, Ken Wong, Nicole Lapuyade, Dylan Daniel
Publikováno v:
Cancer Immunology Research. 9:1451-1464
Immune-checkpoint blockade has revolutionized cancer treatment. However, most patients do not respond to single-agent therapy. Combining checkpoint inhibitors with other immune-stimulating agents increases both efficacy and toxicity due to systemic T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ded81d238596ec1daa607db4fe49c6fc
https://doi.org/10.1158/2326-6066.cir-21-0031
https://doi.org/10.1158/2326-6066.cir-21-0031
Autor:
Alexey Berezhnoy, Hsin Wang, Nicole Lapuyade, Na Cai, Carol LePage, Michael Winter, Michael Krimm, Kenneth Wong, Robert Dunn, Sean McAlister, Leila Boustany, Madan Paidhungat, Marcia Belvin, Erwan Le Scolan, Dylan Daniel
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f7269f85474f794b27cc5d845ebb0af
https://doi.org/10.1136/jitc-2022-sitc2022.1078
https://doi.org/10.1136/jitc-2022-sitc2022.1078
Autor:
Alexey Berezhnoy, Hsin Wang, Nicole Lapuyade, Na Cai, Carol LePage, Michael B. Winter, Ivan Ye, Hong Lu, Michael Krimm, Ken Wong, Robert T. Dunn, Leila Boustany, Madan Paidhungat, Marcia Belvin, Erwan Le Scolan, Dylan Daniel
Publikováno v:
Cancer Research. 82:2071-2071
Type I interferons can exert direct antitumor effects, modulate tumor stroma, and induce de novo antitumor immune responses. They have demonstrated combination activity with PD-(L)1 blockade to potentially expand the benefit to patients with unrespon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::967000bbd415bcbd457aa73c54096d77
https://doi.org/10.1158/1538-7445.am2022-2071
https://doi.org/10.1158/1538-7445.am2022-2071
Autor:
Alexey Berezhnoy, Robert Dunn, Michael Krimm, Marcia Belvin, Hsin Wang, Hikmat Assi, Na Cai, Erwan Le Scolan, Dylan Daniel, Nicole Lapuyade, Kenneth H. S. Wong, Madan M. Paidhungat
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCytokines have been shown to elicit broad anti-tumor activity in preclinical models. These results have translated into the approval for clinical use of IFN-alpha and IL-2 before the checkpoint therapy era. However, to date, the clinical su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5c74af2ab935209c1a95b3793631c3
https://doi.org/10.1136/jitc-2021-sitc2021.706
https://doi.org/10.1136/jitc-2021-sitc2021.706
Autor:
Luc Desnoyers, Yuanhui Huang, Andrew Jang, Elizabeth Menendez, Jason Gary Sagert, Shouchun Liu, Eric Brecht, Olga Vasiljeva, Margaret Nguyen, Nicole Lapuyade, James W. West, Michael Krimm, Annie Yang Weaver, Jeanne Grace Flandez, Stephen R. Moore, Judi Ford, W. Michael Kavanaugh, Linnea Diep, Tereza Sputova, Jonathan A. Terrett, Shweta Singh, Amy DuPage, Jennifer Richardson
Publikováno v:
Molecular Cancer Therapeutics. 14:C165-C165
Antibody drug conjugates (ADCs) have shown their greatest clinical utility when targeting antigens expressed at very high levels on cancer cells that have coincidentally lower expression in normal tissues. This is exemplified by the approvals of tras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dfa74c2d7feb91893fa08e253ae6595
https://doi.org/10.1158/1535-7163.targ-15-c165
https://doi.org/10.1158/1535-7163.targ-15-c165